SCHEDULE: Adage Capital Discloses 7.48% Stake in Centessa Pharma
Beneficial Ownership Report
Adage Capital Management, L.P. and its principals reported a 7.48% beneficial ownership stake in Centessa Pharmaceuticals plc, totaling 10,035,000 ordinary shares.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported beneficial ownership of 10,035,000 ordinary shares of Centessa Pharmaceuticals plc.
- This ownership represents 7.48% of the company's outstanding ordinary shares.
- The percentage is calculated based on 134,073,436 ordinary shares outstanding as of August 1, 2025, as reported in the company's Quarterly Report on Form 10-Q.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership and does not contain information that would significantly alter the fundamental sentiment towards the company, beyond confirming a large institutional stake.
Positives
- A significant institutional investor, Adage Capital Management, maintains a substantial stake in Centessa Pharmaceuticals, indicating continued confidence.
Negatives
- No specific negative information is disclosed in this beneficial ownership report.
Risks
- No specific risks are disclosed in this beneficial ownership report.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing investor confidence and perception of stability.
Key Dates
| Date | Description |
|---|---|
| 2025-08-01 | Date as of which 134,073,436 Ordinary Shares outstanding were reported in the Company's Form 10-Q. |
| 2025-08-12 | Date Centessa Pharmaceuticals plc filed its Quarterly Report on Form 10-Q for the period ended June 30, 2025. |
| 2025-09-30 | Date of event which required the filing of this statement. |
| 2025-11-13 | Date the Schedule 13G Amendment No. 2 was signed by Reporting Persons. |
Keywords
Centessa Pharmaceuticals, Adage Capital Management, Beneficial Ownership, Schedule 13G, CNTA, Institutional Investor, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.